Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Bone Marrow Transplantation volume 49, pages 361–365 (2014)Cite this article

Subjects

Abstract

Previous data suggested that allo-SCT might be an effective therapy in the setting of chemo-refractory/relapsed diseases because of the potent long-term immune-mediated tumor control. This retrospective study aimed to analyze the outcome of adult patients who received allo-SCT in a chemo-refractory/relapsed status. The series included 840 patients with active or progressive disease at the time of transplant. Median age was 50 years. With a median follow-up of 40 months, 3-year OS, disease-free survival (DFS), and non-relapse mortality rates were 29±2, 23±2, and 30±2%, respectively. At the last follow-up, 252 patients (30%) were still alive (of whom 201 were in CR (24%). In a Cox multivariate analysis, the use of a reduced-intensity conditioning (RIC) before allo-SCT and use of an HLA-identical sibling donor remained independently associated with a better OS (hazard ratio (HR)=0.82; 95% confidence interval (CI), 0.69–0.98, P=0.03; and HR=0.79; 95% CI, 0.66–0.93, P=0.006, respectively). Also, a diagnosis of myelodysplastic syndrome/myeloproliferative disorder, Hodgkin lymphoma and non-Hodgkin lymphoma compared with acute leukemia had a favorable impact on OS (HR=0.55; 95% CI, 0.45–0.68, P<0.0001; HR=0.49; 95% CI, 0.31–0.75, P=0.001; and HR=0.47; 95% CI, 0.35–0.63, P<0.0001, respectively). In conclusion, this study suggests that allo-SCT may be of benefit in some subgroups of patients with active or progressive hematological malignancies at the time of allo-SCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    Article  CAS  Google Scholar 

  2. Luznik L, Fuchs EJ . Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2012; 9: 123–137.

    Article  Google Scholar 

  3. Gyurkocza B, Rezvani A, Storb RF . Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev Hematol 2010; 3: 285–299.

    Article  Google Scholar 

  4. Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovo A et al. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Med Wkly 2012; 142: w13696.

    PubMed  Google Scholar 

  5. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990–2010. Bone Marrow Transplant 2012; 47: 906–923.

    Article  CAS  Google Scholar 

  6. Mohty M, Labopin M, Balère ML, Socie G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire. Leukemia 2010; 24: 1867–1874.

    Article  CAS  Google Scholar 

  7. Deeg HJ, Sandmaier BM . Who is fit for allogeneic transplantation? Blood 2010; 116: 4762–4770.

    Article  CAS  Google Scholar 

  8. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.

    Article  CAS  Google Scholar 

  9. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity qconditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.

    Article  CAS  Google Scholar 

  10. Duval M, Klein JP, He Wensheng, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730–3738.

    Article  Google Scholar 

  11. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  Google Scholar 

  12. Fine JP, Gray RJ . A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  13. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867–872.

    Article  CAS  Google Scholar 

  14. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  15. Mohty M, Labopin M, Tabrizzi R, Theorin N, Fauser A, Rambaldi A et al. Reduced-intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008; 93: 303–306.

    Article  Google Scholar 

  16. Terwey TH, Massenkeil G, Tamm I, Hemmati PG, Neuburger S, Martus P et al. Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy. Bone Marrow Transplant 2008; 42: 791–798.

    Article  CAS  Google Scholar 

  17. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H et al. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood 2010; 116: 4368–4375.

    Article  CAS  Google Scholar 

  18. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Fcators predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808–813.

    Article  CAS  Google Scholar 

  19. Bashir Q, Khan H, Orlowski RZ, Amjad AL, Shah N, Parmar S et al. Predictors of prolongad survival alter allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012; 87: 272–276.

    Article  Google Scholar 

  20. Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13: 135–139.

    Article  CAS  Google Scholar 

  21. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008; 93: 257–264.

    Article  CAS  Google Scholar 

  22. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245.

    Article  Google Scholar 

  23. Van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing aftera n autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342–1348.

    Article  Google Scholar 

  24. Le Gouill S, Kroger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695–2703.

    Article  CAS  Google Scholar 

  25. Detrait MY, Chevallier P, Sobh M, Guillaume T, Thomas X, Morisset S et al. Outcome of high-risk and refractory AML/MDS patients receiving a FLAMSA sequential chemotherapy regimen followed by reduced-intensity conditioning (RIC) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Blood (ASH Annual Meeting Abstracts) 2011; 118 Abstract 1957.

  26. Shimoni A, Nagler A . Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still need. Best Pract Res Clin Haematol 2011; 24: 369–379.

    Article  Google Scholar 

  27. Mohty M, Chevallier P . Azacitidine after allo-SCT: the good without the bad? Blood 2012; 119: 3199–3200.

    Article  CAS  Google Scholar 

  28. Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R et al. Long term disease free survival after the MIDAM (Mylotarg, intermediaite dose Ara-C, Mitoxantrone) regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008; 26: 5192–5197.

    Article  CAS  Google Scholar 

  29. Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S et al. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 2013; 161: 659–666.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all the data managers of each centre for data management and collection.

Author Contributions

PC conceived and designed the study, analyzed data, recruited patients, provided clinical care, performed bibliographic search and wrote the manuscript. MM conceived and designed the study, recruited patients, provided clinical care, analyzed data, performed bibliographic search and helped writing the manuscript. ML performed statistical analyses. NM, KB, GS, IY-A, MM, CEB, SM, YB, J-OB, DB, NM, GG, ED recruited patients, provided clinical care and commented on the manuscript. NR performed central data management and collection. All the authors approved the manuscript for publication purposes.

Author information

Authors and Affiliations

  1. Centre Hospitalier et Universitaire (CHU) de Nantes, Hématologie Clinique, Centre d’Investigation Clinique en Cancérologie (CI2C), Université de Nantes and INSERM CRNCA UMR 892, Nantes, France

    P Chevallier

  2. Hématologie Clinique et Thérapie Cellulaire, Hopital Saint-Antoine, APHP, Paris, France

    M Labopin & M Mohty

  3. EBMT, ALWP Office, Hopital Saint Antoine, Paris, France

    M Labopin & M Mohty

  4. Universite Pierre et Marie Curie (UPMC), Paris, France

    M Labopin & M Mohty

  5. INSERM UMRs 938, Paris, France

    M Labopin & M Mohty

  6. Service d’hématologie, CHU et Université de Bordeaux 2 Victor Segalen, Bordeaux, France

    N Milpied

  7. Department of Hematology, Hôpital Hautepierre, CHU, Strasbourg, France

    K Bilger

  8. Department of Hematology-BMT, Hôpital Saint-Louis, Paris, France

    G Socié

  9. Service des Maladies du sang, CHU Hôpital Claude Hurriez, Lille, France

    I Yakoub-Agha

  10. Department of Hematology, BMT Unit, Hôpital Henri Herriot, CHU, Lyon, France

    M Michallet

  11. Department of Hematology, Hopital A. Michallon, CHU, Grenoble, France

    C-E Bulabois

  12. Department of Hematology, Hôpital Henri Mondor, CHU, AP-HP and Faculté de médecine UPEC, Créteil, France

    S Maury

  13. Department of Hematology, University of Liege, CHU Sart-Tilman, Liege, Belgium

    Y Beguin

  14. Department of Hematology, CHU, Clermont-Ferrand, France

    J-O Bay

  15. Unité de Transplantation et de Thérapie cellulaire, Institut Paoli-Calmettes et INSERM UMR 891, Marseille, France

    D Blaise

  16. Department of Hematology, Hopital La Miletrie, CHU, Poitiers, France

    N Maillard

  17. Department of Hematology, CHU, Brest, France

    G Guillerm

  18. Department of Hematology, Hopital Jean Minjoz, CHU, Besancon, France

    E Daguindeau

  19. SFGM-TC, Hôpital Henri Herriot, CHU, Lyon, France

    N Raus

Authors
  1. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Labopin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Bilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C-E Bulabois
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Maury
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Beguin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J-O Bay
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Maillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G Guillerm
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. E Daguindeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. N Raus
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the SFGM-TC

Corresponding author

Correspondence to P Chevallier.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This study was presented as an oral session during the 37th Annual Meeting of the European Group for Blood and Marrow Transplantation (Bone Marrow Transplant 2011; Vol 46 (Supp1): S47 (abstract 0290)).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chevallier, P., Labopin, M., Milpied, N. et al. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant 49, 361–365 (2014). https://doi.org/10.1038/bmt.2013.186

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2013.186

Keywords

This article is cited by

Search

Advanced search

Quick links